Mabcure Stock Performance
| MBCI Stock | USD 0.0001 0.0002 66.67% |
MabCure holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -2.16, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MabCure are expected to decrease by larger amounts. On the other hand, during market turmoil, MabCure is expected to outperform it. Use MabCure standard deviation, kurtosis, period momentum indicator, as well as the relationship between the jensen alpha and day median price , to analyze future returns on MabCure.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MabCure are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating fundamental indicators, MabCure demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3415.00 | |
| Total Cashflows From Investing Activities | 53.2 K |
MabCure |
MabCure Relative Risk vs. Return Landscape
If you would invest 0.01 in MabCure on October 6, 2025 and sell it today you would earn a total of 0.00 from holding MabCure or generate 0.0% return on investment over 90 days. MabCure is currently generating 2.0833% in daily expected returns and assumes 26.4775% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than MabCure, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MabCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MabCure's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as MabCure, and traders can use it to determine the average amount a MabCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0787
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | MBCI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average MabCure is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MabCure by adding it to a well-diversified portfolio.
MabCure Fundamentals Growth
MabCure Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MabCure, and MabCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MabCure Pink Sheet performance.
| Return On Equity | -1.25 | |||
| Return On Asset | -0.0422 | |||
| Operating Margin | (1.42) % | |||
| Current Valuation | 643.64 K | |||
| Shares Outstanding | 64.36 M | |||
| Price To Earning | (0.02) X | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 500 K | |||
| EBITDA | (12.05 M) | |||
| Cash And Equivalents | 146.44 K | |||
| Total Debt | 304.98 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (61.39 K) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 4.81 M | |||
About MabCure Performance
By evaluating MabCure's fundamental ratios, stakeholders can gain valuable insights into MabCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MabCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MabCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. MabCure Inc. was founded in 2006 and is based in White Plains, New York. Mabcure is traded on OTC Exchange in the United States.Things to note about MabCure performance evaluation
Checking the ongoing alerts about MabCure for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MabCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MabCure is way too risky over 90 days horizon | |
| MabCure has some characteristics of a very speculative penny stock | |
| MabCure appears to be risky and price may revert if volatility continues | |
| MabCure has a very high chance of going through financial distress in the upcoming years | |
| MabCure currently holds 304.98 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. MabCure has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist MabCure until it has trouble settling it off, either with new capital or with free cash flow. So, MabCure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MabCure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MabCure to invest in growth at high rates of return. When we think about MabCure's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 500 K. Net Loss for the year was (12.26 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| MabCure currently holds about 146.44 K in cash with (61.39 K) of positive cash flow from operations. | |
| Latest headline from thelincolnianonline.com: Comparing Viper Energy Osage Exploration and Development |
- Analyzing MabCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MabCure's stock is overvalued or undervalued compared to its peers.
- Examining MabCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MabCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MabCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MabCure's pink sheet. These opinions can provide insight into MabCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MabCure Pink Sheet analysis
When running MabCure's price analysis, check to measure MabCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MabCure is operating at the current time. Most of MabCure's value examination focuses on studying past and present price action to predict the probability of MabCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MabCure's price. Additionally, you may evaluate how the addition of MabCure to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |